Black Diamond Therapeutics is an American biotechnology precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. Black Diamond Therapeutics was founded in 2014 and is headquartered in Cambridge, Massachusetts.
P/E
Net profit
P/B
Book value
P/FCF
FCF
Yield
Growth potential
Black Diamond Therapeutics news
12.05.2022
Black Diamond Therapeutics' GAAP loss for 3 months of 2022 was $25.507 million, down 15.8% from $30.301 million in the previous year.
investors.blackdiamondtherapeutics.com
18.03.2022
Black Diamond Therapeutics' GAAP loss for 2021 was $125.596 million, up 86.7% from $67.254 million the previous year.
08.11.2021
Black Diamond Therapeutics' GAAP loss for 9M 2021 was $99.729 million, up 2.2 times from $44.628 million in the previous year.
12.08.2021
Black Diamond Therapeutics' GAAP loss for 6M 2021 was $64.652 million, up 2.4 times from $26.716 million in the previous year.
General information
| Company name | Black Diamond Therapeutics |
|---|---|
| Sector | Health Care / Pharmaceuticals, Biotechnology & Life Sciences / Biotechnology / Biotechnology |
| Business address | 139 Main Street Suite 301 Cambridge, MA 02142 United States |
| Mailing address | 139 Main Street Suite 301 Cambridge, MA 02142 United States |
| Website | investors.blackdiamondtherapeutics.com |
| Information disclosure | www.sec.gov |
English (US) 